ReviewPharmacoEconomics2022
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates.
Review in PharmacoEconomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Does increasing overall health expenditure reduce inequality in under 5 mortality rates between provinces in Indonesia?Health policy and planning · 2026Article
- Comparison of Alternative Outcome Measures in Cost-Effectiveness Analysis: Three Applications Within Oncology.PharmacoEconomics · 2026Article
- Economic Consequences of Increasing the NICE Cost-Effectiveness Threshold.PharmacoEconomics · 2026Article
- A Fully Expert Human-Based Retrieval Augmented Generation (FEH-RAG) Framework: A Proof of Concept Study in Labelling Patients with Sjögren Syndrome.Medical journal of the Islamic Republic of Iran · 2026Article
- Equitable access to costly new drugs.BMJ (Clinical research ed.) · 2025Article
- Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach.PharmacoEconomics · 2025Article
- Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?PharmacoEconomics · 2024Article
- Reply to Comment on "A Framework for Fair Pricing of Medicines".PharmacoEconomics · 2024Article
- A Framework for the Fair Pricing of Medicines.PharmacoEconomics · 2024Article
- Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.Cost effectiveness and resource allocation : C/E · 2023Article
- A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany.Applied health economics and health policy · 2023Article
- The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.PharmacoEconomics · 2023Article
- The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework.Applied health economics and health policy · 2023Article
- Estimating the Health Effects of Expansions in Health Expenditure in Indonesia: A Dynamic Panel Data Approach.Applied health economics and health policy · 2022Article
- Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.Applied health economics and health policy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many health technology assessment committees have an explicit or implicit reference value (often referred to as a 'threshold') below which new health technologies or interventions are considered value for money. The basis for these reference values is unclear but one argument is that it should be based on the health opportunity costs of funding decisions. Empirical estimates of the marginal cost per unit of health produced by a healthcare system have been proposed to capture the health opportunity costs of new funding decisions. Based on a systematic search, we identified eight studies that have sought to estimate a reference value through empirical estimation of the marginal cost per unit of health produced by a healthcare system for England, Spain, Australia, The Netherlands, Sweden, South Africa and China. We review these eight studies to provide an overview of the key methodological approaches taken to estimate the marginal cost per unit of health produced by the healthcare system with the aim to help inform future estimates for additional countries. The lead author for each of these papers was invited to contribute to the current paper to ensure all the key methodological issues encountered were appropriately captured. These included consideration of the key variables required and their measurement, accounting for endogeneity of spending to health outcomes, the inclusion of lagged spending, discounting and future costs, the use of analytical weights, level of disease aggregation, expected duration of health gains, and modelling approaches to estimating mortality and morbidity effects of health spending. Subsequent research estimates for additional countries should (1) carefully consider the specific context and data available, (2) clearly and transparently report the assumptions made and include stakeholder perspectives on their appropriateness and acceptability, and (3) assess the sensitivity of the preferred central estimate to these assumptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.